Abstract
Like in other countries, the reimbursement of vaccination against rotavirus gastroentwritis (RV-G) from public resources in being considered also in the Czech Republic. For this reason, it is necessary to conduct a pharmacoeconomic study to provide the State Institute fo Drug Control with data needed for the evaluation of efficiency of the RV-G vaccination program.This study has been performed from the perspective of public health funds.Base-care assumptions have been: All newborn cgildren will be vaccinated, vaccination will be performed with Rotarix, the reimbursement of cost of one dose of vaccine wil be 1 248.82 CZK, at a 3% discount rate, no health care cost will be saved by the vaccination, no herd immunity will be calculated and quality of life will be calculated only for sick children.
Under these assumption the costs of 1 Quality Adjusted Life Year (QALY) is 1.091 milion CZK, which is just under the willingeness to pay the threshold defined as triple per capita GDP in the Czech Republic. Considering that the cost of QALY in this study is probably overestimated, it is possible to assume that the Rotarix vaccination in the Czech Republic is probably cost effective.